• USPTO issues U.S. Patent No. 12,697,377 B2, covering Nykode’s individualized neoantigen therapy VB10.NEO and related modular neoantigen-based DNA vaccine designs
• Patent provides protection through January 5, 2037, complementing a U.S. patent granted in 2024 covering VB10.NEO
• Recent positive Phase 3 data from Merck and Moderna’s individualized neoantigen therapy program underscores a growing momentum for the INT field
…
Vis børsmeldingen
• Nykode’s VB10.NEO program provides an attractive alternative to mRNA based vaccines enabling expansion to broad set of indications with a reliable and economically supply chain.
Oslo, Norway, August 20, 2026 — Nykode Therapeutics ASA (OSE: NYKD), a clinical stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,697,377 B2, entitled "Therapeutic anticancer neoepitope vaccine” related to its individualized neoantigen therapy pipeline candidate, VB10.NEO.
The newly issued patent relates to Nykode’s fully individualized neoantigen based cancer vaccine, VB10.NEO but also to similar modular neoantigen based cancer vaccines comprising alternative targeting units and/or dimerization units. The 20 year expiration date of this patent is January 5, 2037.
Michael Engsig, CEO of Nykode, said: “This new patent broadens the intellectual property protecting VB10.NEO and our wider neoantigen platform, and it arrives at a pivotal moment for the field. Merck and Moderna’s positive Phase 3 INTerpath-001 data is an important clinical validation of individualized neoantigen cancer vaccines. The question now moves from whether the modality works to which asset can be delivered reliably, and economically, across many indications. With a differentiated APC-targeted design, a neoantigen selection algorithm validated in patients, and an established attractive manufacturing supply chain, we believe VB10.NEO is well positioned to move into a larger set of indications.”
Nykode presented data on the VB10.NEO program at the Neoantigen Summit in Amsterdam on July 22, 2026. Further details are available in the Company’s press releases: Press Releases - Nykode
Nykode is actively exploring partnerships to advance VB10.NEO across a broad range of tumor types.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.
Nykode’s lead product candidates are abi-suva, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in first line head and neck cancer with the randomized Abili-T trial with interim results within 2027. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in two trials with more than 10 different indications.
Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.
Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Contact for Nykode Therapeutics ASA:
IR@nykode.com
Contact for Business Development:
CSO and Co-founder Agnete Fredriksen: BD@nykode.com
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
Kilde
